Welcome to healthcaremagic.com
Currently experts believe that liver injury
due to statins is not as serious as it was thought to be earlier. A dose-related rise in serum aminotransferase levels develops in 1% to 3% of people who take statins (Crestor
is Rosuastatin- a statin). A minor (less than two-fold normal) rise in the serum ALT and AST levels (without symptoms) is the most common manifestation of liver injury with these compounds. These elevations usually reverse rapidly with discontinuation of the statin and also reverse if therapy is not interrupted.
The US Food and Drug Administration labeling information includes liver function testing before and at 12 weeks following the initiation of statins, and at any elevation of dose and periodically thereafter. This recommendation is based upon expert opinion, and many authorities do not feel that routine monitoring of liver function is necessary except to identify and then monitor patients with preexisting liver disease or who are receiving concomitant medications with a potential for drug interactions.
Hence the opinion on this is divided. However most patients in my clinical experience have very little liver effect because of statins and hence my opinion is that going for repeated testing of liver function is not required.